Fig. 1From: In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosisMolecular structure of an MRTF/SRF inhibitor a CCG-222740. b Negative staining transmission electron microscopy of the nanocarrier CCG-222740 formulation. c Size; d Zeta potential; and e Polydispersity index of the nanocarrier CCG-222740 formulation and empty liposomes were measured using a Nano ZS Zetasizer. Results represent mean ± SEM for triplicate measurementsBack to article page